Clinical Trial Search

Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020

Primary: Change in Peripheral Neuropathy Score — 0.3; 0.9 Change in Total Neuropathy Score

Primary: Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigens — 93; 84; 89 Participants

Primary: Disease-free Survival (DFS)- Assessed by Blinded Independent Central Review — 6.8; 5.6 Number of years — p=0.030

Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECT — 100.0; 100.0; 100.0; 100.0 percentage

Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…

Primary: Clinical Global Impression Scale-I (CGI-I) — 3.65; 3.81; 3.86; 4.05 units on a scale

Primary: Percent Change From Baseline in Lumbar Spine BMD — 5.78; 5.73 percent change — p=< 0.001

Primary: Primary Outcome is 4-week Continuous Quit Rate at the End of Treatment. — 1; 5; 7 Participants

Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 61.9; 76.7; 78.1 Percent of participants

Primary: Recurrence Rate at 2 Years — 112; 121; 183; 150 Participants — p=0.1068

Primary: Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20) — 40.2; 69.6; 61.2 percentage of participants — p=0.001

Primary: Number of Participants With Hemostasis at the Target Bleeding Site (TBS) at 3 Minutes Following Treatment Application. — 57; 36 Participants — p=0.0001

Primary: Recurrence Rate at 2 Years — 112; 138; 170; 160 Participants — p=0.1094

Primary: Exertional Dyspnea Intensity at Isotime Exercise. — 3.9; 3.4 units on a scale — p=0.090